Here's which life science companies — in Houston and beyond — are ones to watch. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Last week, the Rice Alliance for Technology and Entrepreneurship gathered over 1,000 life science experts and attendees virtually for thought leadership as well as 40 company presentations.

The three-day 2020 Virtual Texas Life Science Forum was made possible through a partnership with BioHouston and support from Texas Medical Center and Insperity. At the close of the summit, several companies were recognized with awards.

Houston-based Starling Medical won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The digital health device company is revolutionizing severe bladder dysfunction management with artificial intelligence.

Every year at the forum, the Rice Alliance names its 10 most promising companies working on developing innovative solutions in medical devices, digital health, diagnostics, pharmaceuticals, and therapeutics. This year, Brad Burke, managing director of the Rice Alliance, says they had more applications to present than ever before. Additionally, the presenting companies — about half of which are Houston-based — have already raised more than $275 million in funding.

The 2020 most-promising life science companies, which were chosen by investors and presented by the Greater Houston Partnership, were:

Droice Labs

Image via droicelabs.com

New York-based Droice Labs, is an artificial intelligence and big data company matches patients to therapies and delivers personalized medicine at scale while reducing costs.

"Our cutting-edge technology seamlessly integrates into clinical workflows, and we continue to evolve unique and powerful applications for our clients and the patients they serve," reads the company's website.

SFA Therapeutics

Image via sfatherapeutics.com

Based in Jenkintown, Pennsylvania, SFA Therapeutics is developing oral drugs for treating conditions of chronic inflammation that have the potential to change the practice of medicine. The company has treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.

Hummingbird Bioscience

Photo via jlabs.jnjinnovation.com

Hummingbird Bioscience, based in Houston's JLABS @ TMC, is tackling challenging targets that play a key role in disease yet have not been effectively drugged. The company has worked on 12 therapies in various stages of development, four of which have the potential to revolutionize their fields.

"At Hummingbird, we believe that modern approaches to systems biology and data science can overcome the challenges of classical methods of therapeutics discovery, and profoundly improve the way we deliver new transformative medicines," reads the company website.

CaseCTRL

Image via casectrl.com

Houston-based CaseCTRL is empowering surgeons with a management platform with software-as-a-service technology that uses AI and logistics to lower operational costs and simplify surgical planning.

"The surgical scheduling process is frustratingly stuck in the past: siloed, paper-based, and too dependent on single schedulers," reads the website. "Surgeons are stressed and overworked. They need a better way to communicate their complex surgical plans, timelines and resource needs."

Perimeter Medical

Image via perimetermed.com

Perimeter Medical, based in Dallas, is driven to transform cancer surgery with advanced, real-time, ultra high-resolution imaging tools including AI to address areas of unmet medical need.

"Perimeter is dedicated to providing solutions that drive better patient care and lower healthcare costs by providing critical information, during clinical procedures," reads the website.

Studio Bahria

Image via studiobahia.org

San Antonio-based Studio Bahia, is developing an accessible model for therapy in addressing mental health crises from the pandemic through virtual reality.

"We are in production of our first two therapies for release in the 4th quarter of 2020. Studio Bahia clients include corporate, retail, and institutional partners who purchase our headsets for $25 in providing mental health therapies and wellness tools to employees, executives, and patients," reads the company's website.

Tvardi Therapeutics

Photo via Getty Images

Tvardi Therapeutics, based in Houston, is a clinical-stage biopharmaceutical company focused on the development of a new class of breakthrough medicines for diverse cancers and chronic inflammatory and fibrotic diseases.

"Tvardi is focused on the development of orally delivered, small molecule inhibitors of STAT3, a key signaling molecule positioned at the intersection of many disease pathways," reads the website.

Koda Health

Image via kodahealthcare.com

Koda Health, Houston, uses AI to help guide difficult conversations in health care, starting with end-of-life care planning.

"You're entitled to protect the healthcare decisions that matter most to you and your family," the company's website promises. "Koda creates Care Plans to ensure that you get the medical care you want."

Immuno Genesis

Photo via Getty Images

Houston-based ImmunoGenesis is a clinical-stage biotechnology company developing therapeutics to catalyze effective immune responses in immunologically "cold" cancers such as prostate, colorectal, and pancreatic.

"Compared to existing immunotherapy drugs, we believe this antibody will both provide more consistent benefit for patients with immune-infiltrated tumors, and, for the first time, will also benefit patients with immune 'cold' cancers," says founder Dr. Michael A. Curran in a press release announcing the company's grant from the Cancer Prevention and Research Institute of Texas.

Ictero Medical

Image via Getty Images

Ictero Medical, based in Houston, is developing the first minimally invasive cryoablation solution to treat patients with gallstone disease. Ictero Medical has created a minimally invasive treatment, called The CholeSafe System, that uses cryoablation to defunctionize the gallbladder without having to remove it.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston team’s discovery brings solid-state batteries closer to EV use

A Better Battery

A team of researchers from the University of Houston, Rice University and Brown University has uncovered new findings that could extend battery life and potentially change the electric vehicle landscape.

The team, led by Yan Yao, the Hugh Roy and Lillie Cranz Cullen Distinguished Professor of Electrical and Computer Engineering at UH, recently published its findings in the journal Nature Communications.

The work deployed a powerful, high-resolution imaging technique known as operando scanning electron microscopy to better understand why solid-state batteries break down and what could be done to slow the process.

“This research solves a long-standing mystery about why solid-state batteries sometimes fail,” Yao, corresponding author of the study, said in a news release. “This discovery allows solid-state batteries to operate under lower pressure, which can reduce the need for bulky external casing and improve overall safety.”

A solid-state battery replaces liquid electrolytes found in conventional lithium-ion cells with a solid separator, according to Car and Driver. They also boast faster recharging capabilities, better safety and higher energy density.

However, when it comes to EVs, solid-state batteries are not ideal since they require high external stack pressure to stay intact while operating.

Yao’s team learned that tiny empty spaces, or voids, form within the solid-state batteries and merge into a large gap, which causes them to fail. The team found that adding small amounts of alloying elements, like magnesium, can help close the voids and help the battery continue to function. The team captured it in real-time with high-resolution videos that showed what happens inside a battery while it’s working under a scanning electron microscope.

“By carefully adjusting the battery’s chemistry, we can significantly lower the pressure needed to keep it stable,” Lihong Zhao, the first author of this work, a former postdoctoral researcher in Yao’s lab and now an assistant professor of electrical and computer engineering at UH, said in the release. “This breakthrough brings solid-state batteries much closer to being ready for real-world EV applications.”

The team says it plans to build on the alloy concept and explore other metals that could improve battery performance in the future.

“It’s about making future energy storage more reliable for everyone,” Zhao added.

The research was supported by the U.S. Department of Energy’s Battery 500 Consortium under the Vehicle Technologies Program. Other contributors were Min Feng from Brown; Chaoshan Wu, Liqun Guo, Zhaoyang Chen, Samprash Risal and Zheng Fan from UH; and Qing Ai and Jun Lou from Rice.

---

This article originally appeared on EnergyCaptialHTX.com.

Rice biotech accelerator appoints 2 leading researchers to team

Launch Pad

The Rice Biotech Launch Pad, which is focused on expediting the translation of Rice University’s health and medical technology discoveries into cures, has named Amanda Nash and Kelsey L. Swingle to its leadership team.

Both are assistant professors in Rice’s Department of Bioengineering and will bring “valuable perspective” to the Houston-based accelerator, according to Rice. 

“Their deep understanding of both the scientific rigor required for successful innovation and the commercial strategies necessary to bring these technologies to market will be invaluable as we continue to build our portfolio of lifesaving medical technologies,” Omid Veiseh, faculty director of the Launch Pad, said in a news release.

Amanda Nash

Nash leads a research program focused on developing cell communication technologies to treat cancer, autoimmune diseases and aging. She previously trained as a management consultant at McKinsey & Co., where she specialized in business development, portfolio strategy and operational excellence for pharmaceutical and medtech companies. She earned her doctorate in bioengineering from Rice and helped develop implantable cytokine factories for the treatment of ovarian cancer. She holds a bachelor’s degree in biomedical engineering from the University of Houston.

“Returning to Rice represents a full-circle moment in my career, from conducting my doctoral research here to gaining strategic insights at McKinsey and now bringing that combined perspective back to advance Houston’s biotech ecosystem,” Nash said in the release. “The Launch Pad represents exactly the kind of translational bridge our industry needs. I look forward to helping researchers navigate the complex path from discovery to commercialization.”

Kelsey L. Swingle

Swingle’s research focuses on engineering lipid-based nanoparticle technologies for drug delivery to reproductive tissues, which includes the placenta. She completed her doctorate in bioengineering at the University of Pennsylvania, where she developed novel mRNA lipid nanoparticles for the treatment of preeclampsia. She received her bachelor’s degree in biomedical engineering from Case Western Reserve University and is a National Science Foundation Graduate Research Fellow.

“What draws me to the Rice Biotech Launch Pad is its commitment to addressing the most pressing unmet medical needs,” Swingle added in the release. “My research in women’s health has shown me how innovation at the intersection of biomaterials and medicine can tackle challenges that have been overlooked for far too long. I am thrilled to join a team that shares this vision of designing cutting-edge technologies to create meaningful impact for underserved patient populations.”

The Rice Biotech Launch Pad opened in 2023. It held the official launch and lab opening of RBL LLC, a biotech venture creation studio in May. Read more here.

University of Houston archaeologists make history with Mayan tomb discovery

History in the Making

Two University of Houston archaeologists have made scientific history with the discovery of a Mayan king's tomb in Belize.

The UH team led by husband and wife scientists Arlen F. Chase and Diane Z. Chase made the discovery at Caracol, the largest Mayan archeological site in Belize, which is situated about 25 miles south of Xunantunich and the town of San Ignacio. Together with Belize's Institute of Archeology, as well as support from the Geraldine and Emory Ford Foundation and the KHR Family Fund, they uncovered the tomb of Caracol's founder, King Te K’ab Chaak. Their work used airborne light detection and ranging technology to uncover previously hidden roadways and structures that have been reclaimed by the jungle.

The tomb was found at the base of a royal family shrine. The king, who ascended the throne in 331 AD, lived to an advanced enough age that he no longer had teeth. His tomb held a collection of 11 pottery vessels, carved bone tubes, jadeite jewelry, a mosaic jadeite mask, Pacific spondylus shells, and various other perishable items. Pottery vessels found in the chamber depict a Maya ruler wielding a spear as he receives offerings from supplicants represented as deities; the figure of Ek Chuah, the Maya god of traders, surrounded by offerings; and bound captives, a motif also seen in two related burials. Additionally, two vessels had lids adorned with modeled handles shaped like coatimundi (pisote) heads. The coatimundi, known as tz’uutz’ in Maya, was later adopted by subsequent rulers of Caracol as part of their names.

 Diane Chase archaeologist in Mayan tomb Diane Z. Chase in the Mayan tomb. Photo courtesy of University of Houston

During the Classical Period, Caracol was one of the main hubs of the Mayan Lowlands and covered an area bigger than that of present-day Belize City. Populations survived in the area for at least 1,000 years before the city was abandoned sometime around 900 AD. The royal dynasty established by Te K’ab Chaak continued at Caracol for over 460 years.

The find is also significant because this was roughly when the Mexican city of Teotihuacan made contact with Caracol, leading to a long relationship of trade and cultural exchange. Cremation sites found in Caracol contain items that would have come from Teotihuacan, showing the relationship between the two distant cities.

"Both central Mexico and the Maya area were clearly aware of each other’s ritual practices, as reflected in the Caracol cremation," said Arlen F. Chase, professor and chair of Comparative Cultural Studies at the University of Houston.

“The connections between the two regions were undertaken by the highest levels of society, suggesting that initial kings at various Maya cities — such as Te K’ab Chaak at Caracol — were engaged in formal diplomatic relationships with Teotihuacan.”

The Chases will present their findings at a conference on Maya–Teotihuacan interaction hosted by the Maya Working Group at the Santa Fe Institute in New Mexico in August 2025.

 UH professors Chase make Mayan Discovery UH archaeologists Arlen F. Chase and Diane Z. Chase Photo courtesy of University of Houston

 

---

This story originally appeared on CultureMap.com.